The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in‐breast failure in patients with early‐stage breast cancer treated with breast‐conserving therapy

Abstract

Clinical classifications of IBTRs were unreliable methods for determining clonality in many patients. Molecular clonality assays provided a reliable means of identifying patients who may benefit from aggressive systemic therapy at the time of IBTR and also provided a more accurate assessment of the efficacy of various forms of local therapy.